Literature DB >> 2960898

Experimental candidiasis in liver injury.

F Abe1, S Nagata, M Hotchi.   

Abstract

In an attempt to evaluate effects of liver injury and roles of iron metabolism on systemic fungal infection, experimental systemic Candida infection was produced in mice with galactosamine-induced liver injury. Survival rate and extent of fungal lesion are compared between mice with liver injury (Group 1) and ones without liver injury (Group 2). Median survival was 7 and 18 days in Group 1 and 2 respectively after 21 days observation. Mortality rate of Group 1 was significantly higher (P = 0.05) than that of Group 2. This difference was reflected to the extent of fungal lesions in that they were extensive and disseminated, involving the multiple organs in Group 1 but predominantly localized to the kidneys in Group 2. UIBC (unbound iron binding capacity) and TIBC (total iron binding capacity), i.e., serum transferrin as well as serum iron levels were significantly lower in Group 1 as compared with those in Group 2. These results indicate that hepatic injury promotes Candida infection in vivo and suggest that increased susceptibility to Candida in the presence of liver injury is, at least partially, attributable to low UIBC and/or TIBC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960898     DOI: 10.1007/bf00769566

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  13 in total

1.  Fungemia with compromised host resistance. A study of 70 cases.

Authors:  R C Young; J E Bennett; G W Geelhoed; A S Levine
Journal:  Ann Intern Med       Date:  1974-05       Impact factor: 25.391

2.  Experimental hepatitis induced by D-galactosamine.

Authors:  D Keppler; R Lesch; W Reutter; K Decker
Journal:  Exp Mol Pathol       Date:  1968-10       Impact factor: 3.362

3.  Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation.

Authors:  W M Artis; E Patrusky; F Rastinejad; R L Duncan
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

4.  A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability.

Authors:  W M Artis; J A Fountain; H K Delcher; H E Jones
Journal:  Diabetes       Date:  1982-12       Impact factor: 9.461

5.  Disseminated aspergillosis complicating hepatic failure.

Authors:  T J Walsh; S R Hamilton
Journal:  Arch Intern Med       Date:  1983-06

6.  Experimental candidiasis in iron overload.

Authors:  F Abe; M Tateyma; H Shibuya; N Azumi; Y Ommura
Journal:  Mycopathologia       Date:  1985-01       Impact factor: 2.574

7.  Effect of dietary essential amino acid limitations upon the susceptibility to Salmonella typhimurium and the effect upon humoral and cellular immune responses in mice.

Authors:  T M Petro; J K Bhattacharjee
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

8.  Role of iron in the pathogenesis of Vibrio vulnificus infections.

Authors:  A C Wright; L M Simpson; J D Oliver
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

9.  Bacterial and fungal infection in children with fulminant hepatic failure: possible role of opsonisation and complement deficiency.

Authors:  V F Larcher; R J Wyke; A P Mowat; R Williams
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

Review 10.  Antimicrobial properties of iron-binding proteins.

Authors:  A Bezkorovainy
Journal:  Adv Exp Med Biol       Date:  1981       Impact factor: 2.622

View more
  2 in total

Review 1.  Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment.

Authors:  Natália Martins; Isabel C F R Ferreira; Lillian Barros; Sónia Silva; Mariana Henriques
Journal:  Mycopathologia       Date:  2014-05-01       Impact factor: 2.574

2.  Experimental candidiasis associated with liver injury. Role of transferrin.

Authors:  F Abe; T Katoh; H Inaba; M Hotchi
Journal:  Mycopathologia       Date:  1988-10       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.